Adaptimmune Therapeutics plc Stock News

Adaptimmune Therapeutics (NASDAQ: ADAP), a clinical-stage biotech, saw its shares gain an astounding 230% over the month of May, according to data from S&P; Global Market Intelligence. What appears

Scientists at the Department of Energy Manufacturing Demonstration Facility at Oak Ridge National Laboratory have their eyes on the prize: the Transformational Challenge Reactor, or TCR, a microreacto

Today, the truly gullible are being lured by those with a new sales pitch: “Boy, have I got a high-speed rail line for you.”

Jun 04, 2020 (Baystreet.ca via COMTEX) -- There's gold in "them, thar markets," as the old saw goes, and with tension in the world, gold stocks tend to...

Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American D

CAMBRIDGE, Mass., June 4, 2020 /PRNewswire via COMTEX/ -- CAMBRIDGE, Mass., June 4, 2020 /PRNewswire/ -- Artax Biopharma, Inc., a biotechnology company...

Scientists at Seattle Children’s Research Institute and the Benaroya Research Institute have engineered T cells that mimic the immunosuppressive properties of regulatory T cells—an approach that t

Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Extreme Networks Inc, DXC Technology Co, Compugen. Read Harry Boxer's latest article on Investing.com

Biopharma Adaptimmune Therapeutics (ADAP) has now announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at a price to the public of $11

Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.

Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositar

Stocks Analysis by Zacks Investment Research covering: Adaptimmune Therapeutics Plc. Read Zacks Investment Research's latest article on Investing.com

Last Friday, Adaptimmune's shares rocketed higher on the heels of a positive clinical update for its experimental T-cell therapy platform, which was presented at the American Society for Clinical Onco

Adaptimmune Therapeutics plc (NASDAQ:ADAP) shareholders will have a reason to smile today, with the analysts making...

Companies in the news are: ADAP, BIG, YAMHF, CGNX